MARKET

IBRX

IBRX

Immunitybio Inc
NASDAQ
4.330
0.000
0.00%
Opening 09:30 02/07 EST
OPEN
4.350
PREV CLOSE
4.330
HIGH
4.350
LOW
4.310
VOLUME
25.98K
TURNOVER
88.23K
52 WEEK HIGH
7.85
52 WEEK LOW
2.600
MARKET CAP
1.73B
P/E (TTM)
-4.3162
1D
5D
1M
3M
1Y
5Y
BRIEF-Immunitybio Inc Files For Mixed Shelf Of Up To $750 Million - SEC Filing
Reuters · 7h ago
ImmunityBio Reports Positive Data From Metastatic Pancreatic Cancer Study
ImmunityBio Reports Positive Data From Metastatic Pancreatic Cancer Study
MT Newswires · 01/19 12:41
ImmunityBio Isn't Assured Of Bringing Relief For Bladder Cancer
Seeking Alpha · 01/10 06:42
ImmunityBio: Upcoming PDUFA, Solid Data, Confusing Finances
Seeking Alpha · 01/06 19:15
Tesla, Hyzon Motors And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Benzinga · 12/29/2022 13:03
Amyris finalizes $500M deal for license distribution, marketing of two ingredients
Seekingalpha · 12/27/2022 14:17
BRIEF-ImmunityBio Announces $157 Million Financing From Nant And Institutional Investor
Reuters · 12/12/2022 14:16
ImmunityBio to Get $157 Million Financing from Nant, Institutional Investor; Shares Rise
ImmunityBio to Get $157 Million Financing from Nant, Institutional Investor; Shares Rise
MT Newswires · 12/12/2022 11:59
More
About IBRX
Immunitybio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapies and vaccines that improve the immune system to defeat cancers and infectious diseases. Its immunotherapy and cell therapy platforms include antibody cytokine fusion proteins; synthetic immunomodulators; vaccine technologies, which includes human adenovirus (hAd5) viral vector, and genetically modified off-the-shelf natural killer cells (NK cells), which activate both the innate (NK cell and macrophage) and adaptive (T cell) immune systems. Its lead cytokine fusion protein, Anktiva, is an interleukin-15 (IL-15) superagonist complex. Its clinical pipeline consists of approximately 26 actively recruiting clinical trials of which 17 are in Phase II or III development, across 13 indications in liquid and solid tumors, including bladder, pancreatic, and lung cancers, and infectious diseases, including SARS-CoV-2 and human immunodeficiency virus (HIV).

Webull offers kinds of Immunitybio Inc stock information, including NASDAQ:IBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IBRX stock methods without spending real money on the virtual paper trading platform.